- Home
- THRD vs OCCI Comparison
THRD vs OCCI Comparison
Compare THRD & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- OCCI
- Stock Information
- Founded
- THRD 2019
- OCCI N/A
- Country
- THRD United States
- OCCI United States
- Employees
- THRD N/A
- OCCI N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- THRD Health Care
- OCCI Finance
- Exchange
- THRD Nasdaq
- OCCI Nasdaq
- Market Cap
- THRD 164.2M
- OCCI 146.8M
- IPO Year
- THRD 2022
- OCCI N/A
- Fundamental
- Price
- THRD $5.14
- OCCI $6.60
- Analyst Decision
- THRD Hold
- OCCI
- Analyst Count
- THRD 3
- OCCI 0
- Target Price
- THRD $5.00
- OCCI N/A
- AVG Volume (30 Days)
- THRD 1.2M
- OCCI 115.8K
- Earning Date
- THRD 05-14-2025
- OCCI 12-11-2023
- Dividend Yield
- THRD N/A
- OCCI 24.32%
- EPS Growth
- THRD N/A
- OCCI N/A
- EPS
- THRD N/A
- OCCI N/A
- Revenue
- THRD N/A
- OCCI N/A
- Revenue This Year
- THRD N/A
- OCCI N/A
- Revenue Next Year
- THRD N/A
- OCCI $10.19
- P/E Ratio
- THRD N/A
- OCCI N/A
- Revenue Growth
- THRD N/A
- OCCI N/A
- 52 Week Low
- THRD $3.18
- OCCI $5.47
- 52 Week High
- THRD $16.94
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- THRD 79.10
- OCCI 52.98
- Support Level
- THRD $5.08
- OCCI $6.20
- Resistance Level
- THRD $5.20
- OCCI $6.65
- Average True Range (ATR)
- THRD 0.11
- OCCI 0.27
- MACD
- THRD 0.13
- OCCI 0.06
- Stochastic Oscillator
- THRD 96.84
- OCCI 93.06
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.